Catalyst Biosciences (CBIO) vs. Sinovac Biotech (SVA) Critical Analysis

Catalyst Biosciences (NASDAQ: CBIO) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Earnings & Valuation

This table compares Catalyst Biosciences and Sinovac Biotech’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Catalyst Biosciences $400,000.00 385.06 -$16.94 million ($13.12) -2.02
Sinovac Biotech $72.43 million 6.41 -$590,000.00 ($0.01) -813.19

Sinovac Biotech has higher revenue and earnings than Catalyst Biosciences. Sinovac Biotech is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Catalyst Biosciences has a beta of 2.73, suggesting that its stock price is 173% more volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Catalyst Biosciences and Sinovac Biotech, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Biosciences 0 0 3 0 3.00
Sinovac Biotech 0 0 0 0 N/A

Catalyst Biosciences presently has a consensus target price of $13.33, suggesting a potential downside of 49.70%. Given Catalyst Biosciences’ higher probable upside, equities research analysts plainly believe Catalyst Biosciences is more favorable than Sinovac Biotech.

Insider & Institutional Ownership

22.9% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 32.5% of Sinovac Biotech shares are held by institutional investors. 5.0% of Catalyst Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


This table compares Catalyst Biosciences and Sinovac Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalyst Biosciences -2,438.50% -91.67% -55.28%
Sinovac Biotech N/A N/A N/A


Sinovac Biotech beats Catalyst Biosciences on 7 of the 13 factors compared between the two stocks.

About Catalyst Biosciences

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

About Sinovac Biotech

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply